Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy.
about
Considerations for the analysis of longitudinal electronic health records linked to claims data to study the effectiveness and safety of drugs.Gastrointestinal hemorrhage in warfarin anticoagulated patients: incidence, risk factor, management, and outcomeRisk factors associated with uncomplicated peptic ulcer and changes in medication use after diagnosis.One fifth of hospitalizations for peptic ulcer-related bleeding are potentially preventable.Gastrointestinal bleeding in acute ischemic stroke: recent trends from the fukuoka stroke registry.Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidanceEndoscopic management of tumor bleeding from inoperable gastric cancer.Risk of uncomplicated peptic ulcer disease in a cohort of new users of low-dose acetylsalicylic acid for secondary prevention of cardiovascular eventsPPI versus Histamine H2 Receptor Antagonists for Prevention of Upper Gastrointestinal Injury Associated with Low-Dose Aspirin: Systematic Review and Meta-analysisAlternative Medications for Medications in the Use of High-Risk Medications in the Elderly and Potentially Harmful Drug-Disease Interactions in the Elderly Quality Measures.Comorbidities affect risk of nonvariceal upper gastrointestinal bleeding.Discontinuation of low-dose acetylsalicylic acid therapy in UK primary care: incidence and predictors in patients with cardiovascular disease.Prescribing patterns and economic costs of proton pump inhibitors in Colombia.Multidisciplinary management strategies for acute non-variceal upper gastrointestinal bleeding.Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis.Clinical significance of Helicobacter pylori infection in patients with acute coronary syndromes: an overview of current evidence.Management of low-dose aspirin and clopidogrel in clinical practice: a gastrointestinal perspective.Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease.Incidence of upper gastrointestinal haemorrhage in Maori and New Zealand European ethnic groups, 2001-2010.Association of Proton Pump Inhibitors With Reduced Risk of Warfarin-Related Serious Upper Gastrointestinal Bleeding.Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppressionReprescription of low-dose acetylsalicylic acid after discontinuation in patients receiving treatment for secondary cardiovascular disease prevention in the UK.PURLs: The benefits--and limits--of PPIs with warfarin regimens.Effect of rebamipide on gastric bleeding and ulcerogenic responses induced by aspirin plus clopidogrel under stimulation of acid secretion in rats.Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.Risk factors and prevention of dabigatran-related gastrointestinal bleeding in patients with atrial fibrillation.Sepsis as an important risk factor for gastrointestinal bleeding in acute coronary syndrome patients: Two case reports
P2860
Q30251866-95C30E87-3563-4871-8435-9B542E60A4D0Q33760056-9D40C042-7956-4345-B1C9-B836911CA0E7Q33864188-00B3F653-E96F-4F78-8698-72287EB2F19BQ34036732-BF66B8A8-C9EA-4204-AA72-DDB9F3ABC6CCQ34242049-6E46FCD9-9C3C-45DC-BC44-E89CF04831A0Q34655792-69C39878-72E4-4420-B0DD-CC7415924A3AQ34669172-F0A1C67B-3764-4E4A-A793-31DC2B91FEFEQ34746758-F29AAFC7-59CF-484A-9191-EB332288A6ACQ35683846-EF176B1F-7775-4D55-B546-B7F4CF114468Q36961194-D549481D-C831-4EBE-B5E0-11D6D1D33666Q37182009-FD5B2F85-0ADD-456A-A3F3-3FCA48343323Q37300872-8196B1D9-B065-4156-A412-782009AE08B4Q37727492-D3424640-4F93-40F0-9E55-355E158FBB33Q38166285-1E5FFE3E-864F-4785-B9F9-0B8CC57C8089Q38207875-76F95BCA-7899-4F3E-84D0-4FA3C08F938EQ38211000-B220A099-051E-4EEC-AD0B-0152BBBB6EC1Q38321114-F0D41813-E41B-47EE-BB40-7757CD6FC487Q39034536-5FAFD7A0-215D-4108-8953-44AA34656DFFQ39181259-D295EB97-6B45-4633-9D6B-5F6459321D00Q39378104-0F3CC529-4176-4728-81CB-464F9A7701F6Q42371575-829DFC26-52DD-426C-89F5-E95313205927Q45792413-96C907B6-5C55-446F-B62B-8B3BE3B94858Q47171884-E5454EB4-16A2-4B00-80D1-44F147EFFABFQ47772678-9E07873C-5912-4AF9-9888-C25EDD7136DBQ48186337-29FF085E-4FFF-42D5-94BF-3DA313636348Q55263049-EACEBD34-804E-461D-9E08-FC6D8716CFD2Q58759145-D2151973-CACC-4CDF-A0C8-7F5D7C940F96
P2860
Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Acid suppressants reduce risk ...... or anti-inflammatory therapy.
@ast
Acid suppressants reduce risk ...... or anti-inflammatory therapy.
@en
Acid suppressants reduce risk ...... or anti-inflammatory therapy.
@nl
type
label
Acid suppressants reduce risk ...... or anti-inflammatory therapy.
@ast
Acid suppressants reduce risk ...... or anti-inflammatory therapy.
@en
Acid suppressants reduce risk ...... or anti-inflammatory therapy.
@nl
prefLabel
Acid suppressants reduce risk ...... or anti-inflammatory therapy.
@ast
Acid suppressants reduce risk ...... or anti-inflammatory therapy.
@en
Acid suppressants reduce risk ...... or anti-inflammatory therapy.
@nl
P2093
P1433
P1476
Acid suppressants reduce risk ...... or anti-inflammatory therapy.
@en
P2093
Kueiyu Joshua Lin
Luis A García Rodríguez
Sonia Hernández-Díaz
P356
10.1053/J.GASTRO.2011.03.049
P407
P577
2011-03-31T00:00:00Z